Breast cancer metastasis: markers and models
The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant organs. At primary diagnosis, prognostic markers are used to assess whether the transition to systemic disease is likely to have occurred. The prevailing model of metastasis reflects this view--it suggests that metastatic capacity is a late, acquired event in tumorigenesis. Others have proposed the idea that breast cancer is intrinsically a systemic disease. New molecular technologies, such as DNA microarrays, support the idea that metastatic capacity might be an inherent feature of breast tumours. These data have important implications for prognosis prediction and our understanding of metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune cells were shown to both enhance and inhibit malignant cells proliferation, migration, and metastasis [125-128].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [125]
In the citing paper
“Chemical gradients play an important role in tumor cell invasion of metastatic cancer [195,196] as it significantly directs the migration and differentiation of tumor cells.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [196]
In the citing paper
“Metastasis is the leading cause of death from breast cancer1, 37-39.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [1]
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“ERBB2 is overexpressed due to gene amplification in 15–30% of human breast cancer”
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Research works printed but not linked: 2
- Fidler, I. J. Metastasis: quantitative analysis of distribution and fate of tumour embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl Cancer Inst. 45, 773–782 (1970).
- Leighton, J. Inherent malignancy of cancer cells possibly limited by genetically differing cells in the same tumour. Acta Cytol. 9, 138–140 (1965).
Cited by
Items 101–200 of 1,003
Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer
Overall, C. M., & Dean, R. A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7890-0 · Cited by 218
AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
Zhang, Y.-X., Knyazev, P. G., Cheburkin, Y. V., Sharma, K., Knyazev, Y. P., Őrfi, L., Szabadkai, I., Daub, H., Kéri, G., & Ullrich, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2661 · Cited by 210
Breast cancer models: Engineering the tumor microenvironment
Bahcecioglu, G., Basara, G., Ellis, B. W., Ren, X., & Zorlutuna, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.02.006 · Cited by 213
Nanomedicine applications in the treatment of breast cancer: current state of the art
Wu, D., Si, M., Xue, H.-Y., & Wong, H. L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s123437 · Cited by 207
“frequent sites of breast cancer metastasis.(7) Staging is crucial because once the tumor metastasizes, the mortality rate dramatically increases.”
Pádua, D., Rocha, E., Gargiulo, D., & Ramos, A. A. (2015) · Phytochemistry Letters · doi:10.1016/j.phytol.2015.09.007 · Cited by 206
Wiercinska, E., Naber, H. P. H., Pardali, E., van der Pluijm, G., van Dam, H., & ten Dijke, P. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1147-x · Cited by 208
Bailey, J. M., Singh, P. K., & Hollingsworth, M. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21509 · Cited by 209
Advances in drug delivery for post-surgical cancer treatment
Bu, L.-L., Yan, J., Wang, Z., Ruan, H., Chen, Q., Gunadhi, V., Bell, R. B., & Gu, Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.027 · Cited by 207
Matrix metalloproteinases: their functional role in lung cancer
Merchant, N., Nagaraju, G. P., Rajitha, B., Lammata, S., Jella, K. K., Buchwald, Z. S., Lakka, S. S., & Ali, A. N. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx063 · Cited by 206
3D Bioprinted cancer models: Revolutionizing personalized cancer therapy
Augustine, R., Kalva, S. N., Ahmad, R., Zahid, A. A., Hasan, S., Nayeem, A., McClements, L., & Hasan, A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101015 · Cited by 195
miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1
Li, H., Bian, C., Liao, L., Li, J., & Zhao, R. C. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0954-4 · Cited by 202
“common malignant diseases in women and its metastasis at distant sites is the major cause of death [20].”
BackgroundInhibitory effects of chitooligosaccharides on tumor growth and metastasis
Shen, K.-T., Chen, M.-H., Chan, H.-Y., Jeng, J.-H., & Wang, Y.-J. (2009) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.04.044 · Cited by 203
“Metastases are the cause of 90% of human cancer deaths (Weigelt et al., 2005).”
BackgroundInfluence of sex differences on microRNA gene regulation in disease
Sharma, S., & Eghbali, M. (2014) · Biology of Sex Differences · doi:10.1186/2042-6410-5-3 · Cited by 201
A mathematical model of breast cancer development, local treatment and recurrence
Enderling, H., Chaplain, M. A. J., Anderson, A. R. A., & Vaidya, J. S. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2006.12.010 · Cited by 203
“The model framework presented here has predicted that given established mutation rates, there must exist many susceptible genes and stem cells to make breast cancer the most common malignant disease for women today (Weigelt et al., 2005).”
BackgroundComparative biology of human and canine osteosarcoma.
Mueller, F., Fuchs, B., & Kaser‐Hotz, B. (2007) · PubMed · Cited by 258
Revisiting the biological roles of PAI2 (SERPINB2) in cancer
Croucher, D. R., Saunders, D. N., Lobov, S., & Ranson, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2400 · Cited by 200
Vadrevu, S. K., Chintala, N. K., Sharma, S. K., Sharma, P., Cleveland, C., Riediger, L., Manne, S., Fairlie, D. P., Gorczyca, W., Almanza, O., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0157 · Cited by 199
Tumor Microenvironment of Metastasis and Risk of Distant Metastasis of Breast Cancer
Rohan, T. E., Xue, X., Lin, H.-M., D’Alfonso, T. M., Ginter, P. S., Oktay, M. H., Robinson, B. D., Ginsberg, M., Gertler, F. B., Glass, A. G., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju136 · Cited by 202
Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects
Takes, R. P., Rinaldo, A., Silver, C. E., Haigentz, M., Woolgar, J. A., Triantafyllou, A., Mondin, V., Paccagnella, D., de Bree, R., Shaha, A. R., et al. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.03.013 · Cited by 194
“capacity of tumors may differ between cancer types with some having metastatic potential inherently and others acquiring this capacity during progression.(33) Moreover, it may even be that the metastatic capacity of tumors, including HNSCC, may be acquired early in tumor progression.”
BackgroundSopik, V., & Narod, S. A. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4796-9 · Cited by 190
Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer
Moon, P.-G., Lee, J.-E., Cho, Y.-E., Lee, S. J., Chae, Y. S., Jung, J. H., Kim, I.-S., Park, H. Y., & Baek, M.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.9561 · Cited by 193
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
Qin, T., Zeng, Y.-D., Qin, G., Xu, F., Lu, J.-B., Fang, W.-F., Xue, C., Zhan, J.-H., Zhang, X.-K., Zheng, Q.-F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5583 · Cited by 191
Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nilsson, F. Y., Wennborg, A., Abrahmsén, L., & Feldwisch, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2887 · Cited by 193
“However, kidneys are not the main metastatic sites of breast carcinomas (42), the cancer type where (111)In-DOTAZHER2:342-pep2 may have its first clinical use.”
BackgroundXing, F., Kobayashi, A., Okuda, H., Watabe, M., Pai, S. K., Pandey, P. R., Hirota, S., Wilber, A., Mo, Y., Moore, B. E., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201623 · Cited by 190
“Breast cancer is a second leading cause of cancer death among women and more than 90% of deaths are still attributed to metastatic diseases (Jemal et al, 2010; Weigelt et al, 2005).”
Kievit, F. M., Stephen, Z. R., Veiseh, O., Arami, H., Wang, T., Lai, V. P., Park, J. O., Ellenbogen, R. G., Disis, M. L., & Zhang, M. (2012) · ACS Nano · doi:10.1021/nn205070h · Cited by 188
“motherapies, whereas only 40% of them havemetastatic disease.(3) This overtreatment”
InfluentialImproved breast cancer prognosis through the combination of clinical and genetic markers
Sun, Y., Goodison, S., Li, J., Liu, L., & Farmerie, W. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btl543 · Cited by 188
Wu, Z., Wu, Q., Wang, C., Wang, X., Huang, J., Zhao, J., Mao, S., Zhang, G., Xu, X., & Zhang, N. (2011) · Cancer · doi:10.1002/cncr.25860 · Cited by 192
From Nanotechnology to Nanomedicine: Applications to Cancer Research
Seigneuric, R., Markey, L., S.A. Nuyten, D., Dubernet, C., T.A. Evelo, C., Finot, E., & Garrido, C. (2010) · Current Molecular Medicine · doi:10.2174/156652410792630634 · Cited by 182
Torres, L., Ribeiro, F. R., Pandis, N., Andersen, J. A., Heim, S., & Teixeira, M. R. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9317-6 · Cited by 187
“alternative views of the somatic mutation theory of cancer and tumor progression influence how one envisages the development of metastases [3, 4].”
BackgroundSchnittert, J., Bansal, R., Storm, G., & Prakash, J. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.020 · Cited by 188
“4 Metastasis Metastasis, which is defined as the spreading of cells from the primary tumor site to other organs is responsible for more than 90% of cancer-related lethality [114].”
Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis
Stoecklein, N. H., & Klein, C. A. (2010) · International Journal of Cancer · doi:10.1002/ijc.24916 · Cited by 186
Local microRNA delivery targets Palladin and prevents metastatic breast cancer
Gilam, A., Conde, J., Weissglas-Volkov, D., Oliva, N., Friedman, E., Artzi, N., & Shomron, N. (2016) · Nature Communications · doi:10.1038/ncomms12868 · Cited by 186
Thuerigen, O., Schneeweiss, A., Toedt, G., Warnat, P., Hahn, M., Kramer, H., Brors, B., Rudlowski, C., Benner, A., Schuetz, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7019 · Cited by 184
Role of miR-10b in breast cancer metastasis
Ma, L. (2010) · Breast Cancer Research · doi:10.1186/bcr2720 · Cited by 178
“Moreover, current prognostic markers of many cancers, including primary breast carcinomas, only poorly predict eventual metastatic progression [4].”
BackgroundTargeting anoikis resistance in prostate cancer metastasis
Sakamoto, S., & Kyprianou, N. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.001 · Cited by 180
“Metastasis is the spread of tumor cells from a primary tumor to a secondary site in the body remains one of the most life-threatening pathological events, responsible for 90% of cancer death in humans (Weigelt et al., 2005; Yilmaz and Christofori, 2009).”
BackgroundLipid-coated polymeric nanoparticles for cancer drug delivery
Krishnamurthy, S., Vaiyapuri, R., Zhang, L., & Chan, J. M. (2015) · Biomaterials Science · doi:10.1039/c4bm00427b · Cited by 181
Mutant p53–associated myosin-X upregulation promotes breast cancer invasion and metastasis
Arjonen, A., Kaukonen, R., Mattila, E., Rouhi, P., Högnäs, G., Sihto, H., Miller, B. W., Morton, J. P., Bucher, E., Taimen, P., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67280 · Cited by 178
“Introduction Understanding the genesis of motile cancer cells capable of invading the surrounding stroma and disseminating into distant organs is of key importance, since metastases are the main cause of death of patients with cancer (1).”
Revisiting the hallmarks of cancer: The role of hyaluronan
Caon, I., Bartolini, B., Parnigoni, A., Caravà, E., Moretto, P., Viola, M., Karousou, E., Vigetti, D., & Passi, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.007 · Cited by 176
Ling, H., Yang, H., Tan, S., Chui, W., & Chew, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00991.x · Cited by 175
Tenascin C in metastasis: A view from the invasive front
Lowy, C. M., & Oskarsson, T. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1008331 · Cited by 178
Emerging Roles of Electrospun Nanofibers in Cancer Research
Chen, S., Boda, S. K., Batra, S. K., Li, X., & Xie, J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701024 · Cited by 170
Luo, L., Zhu, C., Yin, H., Jiang, M., Zhang, J., Qin, B., Luo, Z., Yuan, X., Yang, J., Li, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00204 · Cited by 177
Micromanagers of malignancy: role of microRNAs in regulating metastasis
Ma, L., & Weinberg, R. A. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.06.004 · Cited by 173
“Such prognostic markers continue to be highly sought, because current prognosticmarkersofmanycancers,suchasprimarybreast carcinomas, only poorly predict eventual metastatic progression [ 44 ].”
Emerging strategies for treating metastasis
Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 172
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., & Li, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00747-x · Cited by 163
“Bone metastases are common in breast cancer, with nearly 70% of advanced breast cancer patients developing bone metastasis (BM) [43, 44].”
BackgroundCancer Stem Cell Plasticity Drives Therapeutic Resistance
Doherty, M., Smigiel, J., Junk, D., & Jackson, M. (2016) · Cancers · doi:10.3390/cancers8010008 · Cited by 160
Jackson, J. M., Witek, M. A., Kamande, J. W., & Soper, S. A. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00016b · Cited by 172
Cardoso, B. D., Castanheira, E. M. S., Lanceros‐Méndez, S., & Cardoso, V. F. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202936 · Cited by 161
McDowell, S. A. C., Luo, R. B. E., Arabzadeh, A., Doré, S., Bennett, N. C., Breton, V., Karimi, E., Rezanejad, M., Yang, R. R., Lach, K. D., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00194-9 · Cited by 164
Lee, J., Lim, T., Uhm, J. E., Park, K. W., Park, S. H., Lee, S. C., Park, J. O., Park, Y. S., Lim, H. Y., Sohn, T. S., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl501 · Cited by 169
“Prognostic scoring systems have been delineated in several cancer types and are being increasingly used in clinics to segregate different risk groups for patients with aggressive lymphoma [9], breast cancer [10, 11], prostate cancer [12], multiple myeloma [13], esophageal/gastroesophageal junction tumors/gastric cance…”
BackgroundVasculature-On-A-Chip for In Vitro Disease Models
Kim, S., Kim, W., Lim, S., & Jeon, J. (2017) · Bioengineering · doi:10.3390/bioengineering4010008 · Cited by 157
Liu, Y., Ge, J., Chen, Y., Liu, T., Chen, L., Liu, C., Ma, D., Chen, Y., Cai, Y., Xu, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202205395 · Cited by 159
Metastasis review: from bench to bedside
Alizadeh, A. M., Shiri, S., & Farsinejad, S. (2014) · Tumor Biology · doi:10.1007/s13277-014-2421-z · Cited by 160
Wang, D., Xu, Z., Yu, H., Chen, X., Feng, B., Cui, Z., Lin, B., Yin, Q., Zhang, Z., Chen, C., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.094 · Cited by 163
Cell survival and metastasis regulation by Akt signaling in colorectal cancer
Agarwal, E., Brattain, M. G., & Chowdhury, S. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.03.025 · Cited by 165
Madhavan, D., Wallwiener, M., Bents, K., Zucknick, M., Nees, J., Schott, S., Cuk, K., Riethdorf, S., Trumpp, A., Pantel, K., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2946-2 · Cited by 161
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition in Cancer Metastasis
Celià-Terrassa, T., & Jolly, M. K. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036905 · Cited by 163
MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer
Yu, S.-J., Hu, J.-Y., Kuang, X.-Y., Luo, J.-M., Hou, Y.-F., Di, G.-H., Wu, J., Shen, Z.-Z., Song, H.-Y., & Shao, Z.-M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1959 · Cited by 159
TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway
Meng, X., Cai, C., Wu, J., Cai, S., Ye, C., Chen, H., Yang, Z., Zeng, H., Shen, Q., & Zou, F. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.031 · Cited by 170
Nolé, F., Munzone, E., Zorzino, L., Minchella, I., Salvatici, M., Botteri, E., Medici, M., Verri, E., Adamoli, L., Rotmensz, N., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm558 · Cited by 159
Kowalik, A., Kowalewska, M., & Góźdź, S. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.04.002 · Cited by 164
Cancer-associated bone disease
Rizzoli, R., Body, J. J., Brandi, M. L., Cannata-Andía, J. B., Chappard, D., Maghraoui, A. E., Glüer, C.-C., Kendler, D., Napoli, N., Παπαϊωάννου, Α., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2530-3 · Cited by 163
“Metastases from cancer are associated with 90 % of cancer deaths [3].”
BackgroundIdentity Profiling of Cell Surface Markers by Multiplex Gold Nanorod Probes
Yu, C., Nakshatri, H., & Irudayaraj, J. (2007) · Nano Letters · doi:10.1021/nl070894m · Cited by 155
The Long Journey of Cancer Biomarkers from the Bench to the Clinic
Pavlou, M. P., Diamandis, E. P., & Blasutig, I. M. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.184614 · Cited by 145
Cancer Cell Invasion: Treatment and Monitoring Opportunities in Nanomedicine
Veiseh, O., Kievit, F. M., Ellenbogen, R. G., & Zhang, M. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.01.010 · Cited by 158
Yaal-Hahoshen, N., Shina, S., Leider-Trejo, L., Barnea, I., Shabtai, E. L., Azenshtein, E., Greenberg, I., Keydar, I., & Ben-Baruch, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0074 · Cited by 150
Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
Agnoletto, C., Corrà, F., Minotti, L., Baldassari, F., Crudele, F., Cook, W. J. J., Leva, G. D., D’Adamo, P., Gasparini, P., & Volinia, S. (2019) · Cancers · doi:10.3390/cancers11040483 · Cited by 152
Hanada, R., Hanada, T., Sigl, V., Schramek, D., & Penninger, J. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0749-z · Cited by 154
Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes
Ullah, I., Karthik, G.-M., Alkodsi, A., Kjällquist, U., Stålhammar, G., Lövrot, J., Martinez, N.-F., Lagergren, J., Hautaniemi, S., Hartman, J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96149 · Cited by 154
18F, 64Cu, and 68Ga Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of Breast Cancer
Liu, Z., Yan, Y., Liu, S., Wang, F., & Chen, X. S. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9000245 · Cited by 145
Yu, Y., Luo, W., Yang, Z., Chi, J.-R., Li, Y.-R., Ding, Y., Ge, J., Wang, X., & Cao, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0818-9 · Cited by 152
Reddy, L. H., Dubernet, C., Lepêtre‐Mouelhi, S., Marque, P. E., Desmaële, D., & Couvreur, P. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.018 · Cited by 143
Wei, X., Wang, Y., Xiong, X., Guo, X., Zhang, L., Zhang, X., & Zhou, S. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603336 · Cited by 151
Zhao, H., Xu, J., Feng, C., Ren, J., Bao, L., Zhao, Y., Tao, W., Zhao, Y., & Yang, X. (2022) · Advanced Materials · doi:10.1002/adma.202106390 · Cited by 142
Alterations in the Smad pathway in human cancers
Samanta, D., & Datta, P. K. (2011) · Frontiers in bioscience · doi:10.2741/3986 · Cited by 143
Mekhdjian, A. H., Kai, F., Rubashkin, M. G., Prahl, L. S., Przybyla, L., McGregor, A., Bell, E. S., Barnes, J. M., DuFort, C. C., Ou, G., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-09-0654 · Cited by 148
Probing the Microenvironment of Mammary Tumors Using Multiphoton Microscopy
Sidani, M., Wyckoff, J. B., Xue, C., Segall, J. E., & Condeelis, J. S. (2006) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9021-5 · Cited by 141
Biswas, S., Sengupta, S., Chowdhury, S. R., Jana, S., Mandal, G., Mandal, P., Saha, N., Malhotra, V., Gupta, A., Kuprash, D. V., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2811-8 · Cited by 144
Zhang, G., Zhang, W., Li, B., Stringer-Reasor, E. M., Chu, C., Sun, L., Bae, S., Chen, D., Wei, S., Jiao, K., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0858-x · Cited by 141
The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
McLaughlin, S. K., Olsen, S. N., Dake, B., De Raedt, T., Lim, E., Bronson, R. T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.004 · Cited by 135
Barcus, C. E., O’Leary, K. A., Brockman, J. L., Rugowski, D. E., Liu, Y., Garcia, N., Yu, M., Keely, P. J., Eliceiri, K. W., & Schuler, L. A. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0801-1 · Cited by 135
“ERα + breast cancers metastasize to multiple peripheral tissues, including the lungs [44].”
Mobile Magnetic Nanocatalysts for Bioorthogonal Targeted Cancer Therapy
Hoop, M., Ribeiro, A. S., Rösch, D., Weinand, P., Mendes, N. M., Mushtaq, F., Chen, X., Shen, Y., Franco, C., Puigmartí‐Luis, J., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201705920 · Cited by 140
Huang, J., Wei, F.-K., Xu, X., Ye, S.-X., Song, J., Ding, P., Zhu, J., Li, H.-F., Luo, X., Gong, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1895-2 · Cited by 138
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness
Pegoraro, S., Ros, G., Piazza, S., Sommaggio, R., Ciani, Y., Rosato, A., Sgarra, R., Sal, G. D., & Manfioletti, G. (2013) · Oncotarget · doi:10.18632/oncotarget.1136 · Cited by 145
Cardone, R. A., Bellizzi, A., Busco, G., Weinman, E. J., Dell'Aquila, M. E., Casavola, V., Azzariti, A., Mangia, A., Paradiso, A., & Reshkin, S. J. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-07-0617 · Cited by 135
Xing, F., Liu, Y., Sharma, S., Wu, K., Chan, M. D., Lo, H., Carpenter, R. L., Metheny‐Barlow, L. J., Zhou, X., Qasem, S. A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3541 · Cited by 143
Tunneling nanotubes, a novel mode of tumor cell–macrophage communication in tumor cell invasion
Hanna, S. J., McCoy-Simandle, K., Leung, E., Genna, A., Condeelis, J. S., & Cox, D. (2019) · Journal of Cell Science · doi:10.1242/jcs.223321 · Cited by 143
Freudenberg, J. A., Wang, Q., Katsumata, M., Drebin, J. A., Nagatomo, I., & Greene, M. I. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.05.001 · Cited by 149
Wang, F., Xue, X., Wei, J., An, Y., Yao, J. J., Cai, H., Wu, J., Dai, C., Qian, Z., Xu, Z., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605724 · Cited by 140
RetractedWang, C., Lai, M.-D., Phan, N. N., Sun, Z., & Lin, Y.-C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125766 · Cited by 153
Dysregulated miR-183 inhibits migration in breast cancer cells
Lowery, A., Miller, N., Dwyer, R. M., & Kerin, M. J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-502 · Cited by 143
“This is hugely significant as metastasis is the overwhelming cause of mortality in breast cancer patients, but a complete understanding of its molecular and cellular determinants remains elusive [36].”
Priming the ‘Soil’ for Breast Cancer Metastasis: The Pre-Metastatic Niche
Psaila, B., Kaplan, R. N., Port, E. R., & Lyden, D. (2007) · Breast Disease · doi:10.3233/bd-2007-26106 · Cited by 133
“Breast cancer is the leading cause of cancer mortality in women, the vast majority of which is due to metastatic disease [3,4].”
DEAD-box helicase DP103 defines metastatic potential of human breast cancers
Shin, E. M., Sin Hay, H., Lee, M. H., Goh, J. N., Tan, T. Z., Sen, Y. P., Lim, S. W., Yousef, E. M., Ong, H. T., Thike, A. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73451 · Cited by 132
Baklaushev, V. P., Kilpeläinen, A., Petkov, S., Abakumov, M. A., Grinenko, N. F., Yusubalieva, G. M., Latanova, A. A., Gubskiy, I. L., Zabozlaev, F. G., Starodubova, E. S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07851-z · Cited by 121
Engineering the pre-metastatic niche
Aguado, B. A., Bushnell, G. G., Rao, S. S., Jeruss, J. S., & Shea, L. D. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0077 · Cited by 125
Mechanisms of bone metastases of breast cancer
Suva, L. J., Griffin, R. J., & Makhoul, I. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0012 · Cited by 144
“Two fundamentally different models for metastasis have been described (Weigelt et al. 2005).”
Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer
Johnson, A. L., Edson, K. Z., Totah, R. A., & Rettie, A. E. (2015) · Advances in pharmacology · doi:10.1016/bs.apha.2015.05.002 · Cited by 141
Yoshihara, E., Smeets, A., Laenen, A., Reynders, A., Soens, J., Ongeval, C. V., Moerman, P., Paridaens, R., Wildiers, H. P. M. W., Neven, P., et al. (2012) · The Breast · doi:10.1016/j.breast.2012.09.003 · Cited by 130
Li, Z., Mo, F., Wang, Y., Li, W., Chen, Y., Liu, J., Chen‐Mayfield, T., & Hu, Q. (2022) · Nature Communications · doi:10.1038/s41467-022-34036-8 · Cited by 142
Murakami, M., Ernsting, M. J., Undzys, E., Holwell, N., Foltz, W. D., & Li, S.-D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0062 · Cited by 129
Metadata
- Authors
- Weigelt, B., Peterse, J. L., & van't Veer, L. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- ORCID
- Weigelt, Britta
- Venue
- Nature Reviews Cancer
- Published
- 2005-08-01
- Volume
- 5
- Issue
- 8
- Pages
- 591-602
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2004280628
- Semantic Scholar
- 3bd1490d7b6c8daa59bd35260c6c71e39d3d62fa
- Cited by
- 2,232
- References
- 112
- Citations by year
- 2026: 34 · 2025: 69 · 2024: 90 · 2023: 111 · 2022: 139 · 2021: 154 · 2020: 159 · 2019: 147 · 2018: 140 · 2017: 191 · 2016: 162 · 2015: 152 · 2014: 121 · 2013: 104 · 2012: 88
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- breast cancer, metastasis, prognostic factors, metastatic potential, lymph node metastasis, distant metastasis, carcinogenesis, DNA microarrays, systemic disease, metastasis model
- MeSH terms
- Breast Neoplasms, Female, Humans, Neoplasm Metastasis, Biomarkers, Tumor, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.